Tandem Secures $100M Funding to Revolutionize Medical Prescription Paperwork with AI

Tandem, a New York-based company, is making waves in the healthcare sector by using cutting-edge Generative AI to automate the complex process of writing and receiving medical prescriptions. Their impressive $100M Series B funding round at a $1B valuation signifies a strong vote of confidence in their innovative approach to streamlining medical administration. This innovative use of AI promises to enhance efficiency and reduce administrative burdens.

• •Tandem employs AI to automate medical prescription processes.
• •The company secured a $100M Series B funding round.
• •The funding values Tandem at $1 billion.